Recent

% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

  • vercingentorix666 vercingentorix666 Aug 5, 2014 11:27 PM Flag

    FDA accepted the IND for IPF

    Roche is recruiting now !!!

    NEWS TOMORROW !!!

    $ 10 soon, very very soon.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
      This study is currently recruiting participants. (see Contacts and Locations)
      Verified August 2014 by Hoffmann-La Roche
      Sponsor:
      Hoffmann-La Roche
      Information provided by (Responsible Party):
      Hoffmann-La Roche
      ClinicalTrials.gov Identifier:
      NCT02168530
      First received: June 18, 2014
      Last updated: August 4, 2014
      Last verified: August 2014
      History of Changes
      Full Text View Tabular ViewNo Study Results PostedDisclaimerHow to Read a Study Record
      Purpose
      This is a randomized, multicenter, double-blind, placebo-controlled, parallel-gr oup study of vismodegib in patients with IPF. Eligible patients will be randomiz ed in a 2:1 ratio to one of two treatment arms: vismodegib or placebo. The durat ion of treatment will be 52 weeks. Study drug will be administered daily by the oral route. An 8-week safety follow-up period is included for all patients who r eceive at least one dose of study drug.

      Condition Intervention Phase
      Idiopathic Pulmonary Fibrosis
      Drug: vismodegib
      Drug: placebo
      Phase 2

      Sentiment: Strong Buy

 
CRIS
2.88Apr 27 4:00 PMEDT